CIK 0001651308 · Large accelerated filer
BeOne Medicines Ltd.
Sign in to watch- Ticker
- BEIGF
- Exchange
- Nasdaq, OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 981209416
- Phone
- 41-616851900
- Business address
- C/O BEONE MEDICINES I GMBH, AESCHENGRABEN 27, 21ST FLOOR, BASEL, Switzerland, 4051
- Former names
- BeiGene, Ltd.
Securities
- ONC American Depositary Shares Nasdaq
- BEIGF Common stock OTC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $48,487,541
- in 9 filings, $47.8M under 10b5-1 plans
Net −$48,487,541. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-08-13 | Lee Chan Henry SVP, General Counsel | Option exercise 10b5-1 | +3,849 | $159.03 | $612K | 8,230 |
| 2025-08-13 | Lee Chan Henry SVP, General Counsel | Sale 10b5-1 | −6,052 | $300.19 | $1.8M | 2,178 |
| 2025-08-13 | Lee Chan Henry SVP, General Counsel | Sale 10b5-1 | −3,849 | $301.00 | $1.2M | 0 |
| 2025-08-13 | Lee Chan Henry SVP, General Counsel | Option exercise · Share Option (Right to Buy) 10b5-1 | −56,953 | 131,976 | ||
| 2025-08-13 | Lee Chan Henry SVP, General Counsel | Option exercise · Share Option (Right to Buy) 10b5-1 | −50,037 | 134,758 | ||
| 2025-08-01 | Rosenberg Aaron Chief Financial Officer | Sale | −1,190 | $290.47 | $346K | 0 |
| 2025-07-30 | Wang Lai Global Head of R&D | Sale 10b5-1 | −259 | $305.00 | $79K | 0 |
| 2025-07-30 | Lee Chan Henry SVP, General Counsel | Sale | −920 | $304.60 | $280K | 0 |
| 2025-07-29 | Wang Lai Global Head of R&D | Sale 10b5-1 | −2,949 | $302.00 | $891K | 1,351 |
| 2025-07-29 | Wang Lai Global Head of R&D | Sale 10b5-1 | −292 | $302.92 | $88K | 1,059 |
| 2025-07-29 | Wang Lai Global Head of R&D | Sale 10b5-1 | −800 | $304.16 | $243K | 259 |
| 2025-07-18 | Wang Lai Global Head of R&D | Sale 10b5-1 | −700 | $300.00 | $210K | 0 |
| 2025-07-09 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −6,703 | $252.23 | $1.7M | 21,099 |
| 2025-07-09 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −9,292 | $253.18 | $2.4M | 11,807 |
| 2025-07-09 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −10,254 | $254.10 | $2.6M | 1,553 |
| 2025-07-09 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −1,553 | $254.83 | $396K | 0 |
| 2025-06-24 | Wang Xiaodong Director | Sale 10b5-1 | −300 | $263.50 | $79K | 1,707 |
| 2025-06-24 | Wang Xiaodong Director | Sale 10b5-1 | −1,100 | $265.35 | $292K | 607 |
| 2025-06-24 | Wang Xiaodong Director | Sale 10b5-1 | −507 | $266.57 | $135K | 100 |
| 2025-06-24 | Wang Xiaodong Director | Sale 10b5-1 | −100 | $267.81 | $27K | 0 |
Page 22 of 71 · 1,406 trades